FDA Proposes Crackdown on Synthetic Kratom Derivative, Citing Opioid-Like Dangers

In a critical move to combat a potential new front in the opioid crisis, the FDA has announced its intention to classify 7-hydroxymitragynine (7-OH), a potent derivative of the kratom plant, as a Schedule I controlled substance. This action, announced in July 2025, is specifically aimed at highly concentrated, synthetic forms of 7-OH, not the traditional kratom leaf itself.

The Dangerous Potency of Synthetic 7-OH

While natural kratom (Mitragyna speciosa) contains less than 2% 7-OH by total alkaloid content, a new generation of unregulated, man-made products—marketed as gummies, tablets, and drinks—can contain as much as 98% 7-OH. This significant concentration makes them far more potent and dangerous than natural kratom. Research indicates that 7-OH can cause respiratory depression at a potency over three times that of morphine and binds to mu-opioid receptors at a rate 10 to 13 times higher.

The body’s metabolism converts the primary kratom alkaloid, mitragynine, into 7-OH. Unlike mitragynine, which has a unique pharmacological profile, 7-OH acts as a classic opioid. Its effects, which include the potential for tolerance, dependence, and withdrawal, can be reversed by naloxone, further solidifying its classification as a dangerous opioid.

Government Action and Public Health Warnings

Following a risk assessment, the FDA issued warning letters to seven companies for illegally marketing potent 7-OH products as “dietary supplements” or foods. This action is a direct response to growing public health concerns. “After the last wave of the opioid epidemic, we cannot get caught flat-footed again,” said Marty Makary, MD, MPH, in a news release, highlighting the need for regulation and public education to prevent another crisis.

While the FDA is targeting synthetic 7-OH, the natural kratom leaf remains legal at the federal level and in many states. The National Institute on Drug Abuse (NIDA) acknowledges that some users find kratom helpful for pain and opioid withdrawal, but also notes that adverse events are often linked to contaminated or adulterated products, or polysubstance abuse.

The Role of Pharmacists and Consumer Education

The FDA’s proposed scheduling of 7-OH may encourage states to follow suit with their own bans, similar to those already in place in Virginia and Arizona. The rise in kratom-related emergency room visits and poison control calls, particularly involving interactions with other sedatives, underscores the urgent need for awareness.

It is crucial for pharmacists and consumers to understand the stark difference between natural kratom and high-potency “enhanced” 7-OH products. The latter represents a significant, unregulated opioid threat that is readily available and poses a major risk of addiction and overdose. Educating the public about this distinction is a critical step in mitigating harm.